FASN and CD36 predict survival in rituximab-treated diffuse large B-cell lymphoma

Area of Science:

• Oncology
• Metabolic pathways
• Hematologic malignancies

Background:

• Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin's lymphoma, with variable patient outcomes.
• Identifying prognostic factors is crucial for refining treatment strategies in DLBCL.
• De novo fatty acid synthesis is a key metabolic pathway implicated in tumor progression across various cancers.

Purpose of the Study:

• To investigate the clinical significance of fatty acid synthase (FASN), Spot 14, and CD36 expression in DLBCL.
• To determine if these factors serve as prognostic markers for patient survival and treatment response.

Main Methods:

• Retrospective analysis of FASN, Spot 14, and CD36 expression in DLBCL patient samples.
• Correlation of protein expression levels with overall survival and progression-free survival.
• Multivariate analysis to identify independent prognostic markers.

Main Results:

• FASN overexpression is significantly associated with shorter overall survival (p=0.001) and progression-free period (p=0.004) in DLBCL patients.
• FASN overexpression was identified as an independent prognostic marker for an aggressive clinical course.
• CD36 was found to be an independent protective factor in DLBCL patients treated with rituximab.

Conclusions:

• FASN and CD36 expression levels may serve as valuable prognostic markers for predicting treatment response and survival in DLBCL.
• FASN represents a potential therapeutic target for lymphoid malignancies.
• CD36 may play a protective role in rituximab-treated DLBCL patients.